On July 9, Insilico Medicine rose 5.89% in regular trading, trading at HKD 38.78/share, with turnover of HKD 234 million. The rally was driven by the company's positive profit warning issued earlier in the day.

Insilico Medicine announced that based on preliminary assessment of unaudited consolidated management accounts for H1, revenue is expected to reach approximately USD 103 million to USD 107 million, representing a year-over-year increase of approximately 272.7% to 287.3% compared to USD 27.5 million in the prior year period. Net profit is projected at USD 33.5 million to USD 39.5 million, compared to a net loss of USD 19.2 million in H1 of the prior year, marking a significant turnaround from loss to profitability. Adjusted non-IFRS net profit is expected at USD 45.5 million to USD 51.5 million versus a prior year adjusted net loss of USD 15.4 million.

The profit alert follows a series of recent catalysts including the initiation of a Phase 3 clinical trial for its AI-discovered drug Rentosertib on July 8 and a strategic collaboration with Takeda Pharmaceutical valued at up to USD 600 million announced on July 2.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)